Randomized Phase II Trial of Erlotinib in Combination with High Dose-Celecoxib or Placebo in Patients with Advanced Non-small Cell Lung Cancer

BACKGROUND: Cyclooxygenase-2 (COX-2)-dependent signaling represents a potential mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. This is mediated in part through an EGFR-independent activation of MAPK/Erk by PGE2. PGE2 promotes downregulatio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Reckamp, Karen L., Koczywas, Marianna, Cristea, Mihaela C., Dowell, Jonathan E., Wang, He-Jing, Gardner, Brian, Milne, Ginger L., Figlin, Robert A., Fishbein, Michael C., Elashoff, Robert M., Dubinett, Steven M.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4864011/
https://ncbi.nlm.nih.gov/pubmed/26033830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29480
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars